WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced its agreement to acquire BIOTRONIK’s Vascular Intervention business in a transaction valued at approximately €760 million. With this strategic acquisition, Teleflex aims to strengthen its position in the $10 billion interventional cardiology and peripheral vascular markets, significantly broadening its product portfolio and advancing its long-term growth strategy. The deal is expected to close by the end of the third quarter of 2025, pending regulatory approvals and customary conditions.
Strategic Advancements
The acquisition will expand Teleflex’s offerings to include a comprehensive range of vascular intervention devices, such as drug-coated balloons, drug-eluting stents, covered stents, and innovative balloon catheters. Approximately 75% of the acquired revenues stem from coronary interventions, with the remainder focused on peripheral vascular procedures.
“We are excited to announce the acquisition of BIOTRONIK’s Vascular Intervention business, which we anticipate will significantly enhance our global presence in the cath lab, expand our suite of innovative technologies, and improve patient care,” said Liam Kelly, Chairman, President, and Chief Executive Officer of Teleflex. He added, “We believe the acquisition will allow us to position this advanced coronary portfolio alongside our existing Interventional business and establish our global footprint in the fast-growing peripheral intervention market.”
Notable additions include the Pantera™ Lux™ Drug-Coated Balloon Catheter and Orsiro™ Mission Drug-Eluting Stent for coronary interventions, as well as the Passeo™-18 Lux™ Peripheral Drug-Coated Balloon Catheter and Pulsar™-18 T3 Self-Expanding Stent for peripheral applications.
Innovation Pipeline and Market Impact
The deal provides Teleflex access to BIOTRONIK’s cutting-edge technologies, including Freesolve™, a sirolimus-eluting Resorbable Metallic Scaffold (RMS) recently approved in Europe. Freesolve™ aligns with the trend of reducing permanent hardware in vascular procedures, offering temporary scaffolding with drug delivery. Clinical results from the BIOMAG-I study demonstrated encouraging safety and effectiveness, with ongoing trials like BIOMAG-II further exploring its potential.
The acquisition underscores Teleflex’s commitment to innovation, with Kelly noting the business’s foundation in “robust research and development, clinical expertise, and global manufacturing capabilities.” The company’s established clinical platform and outreach programs will further support the integration and expansion of these advanced vascular solutions.
Financial Outlook
The acquired products demonstrated a constant currency CAGR of 5.4% from 2022 to 2024, with expected revenues of approximately €91 million in the fourth quarter of 2025. Beginning in 2026, the business is projected to achieve revenue growth of 6% or higher on a constant currency basis.
Teleflex anticipates the deal will add $0.10 to adjusted earnings per share within the first year of ownership, with increasing accretion over subsequent years. The acquisition will initially be financed through a mix of term loans, existing credit facilities, and cash on hand, with foreign exchange hedges in place to mitigate currency risks.
Positioned for Growth
This acquisition positions Teleflex as a stronger player in the global interventional cardiology and vascular markets. By combining BIOTRONIK’s advanced technologies with its own innovations, the company aims to enhance patient outcomes while driving sustainable growth. With a meaningful contribution to its portfolio and geographic revenue diversification, Teleflex reinforces its vision to lead in life-saving technologies worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.